News

Analysis of nearly 15k patients with non-dialysis-dependent CKD and anemia provides insight into contemporary trends in management.

Preliminary data from the open-label RUBY-3 trial were presented at the American Society of Nephrology Kidney Week 2023.

Results from the phase 2/3 DIAMOND trial show a significant reduction in central macular thickness and significant visual gain in eyes treated with OCS-01 drops versus sham.

New, 2-year results from the phase 3 PHOTON study show continued benefit for patients with diabetic macular edema treated with aflibercept 8mg.

This research highlights the close relationship between pollen-induced allergic rhinitis, sensitization, and asthma.

Despite recommendations to consult with ophthalmologists prior to initiating semaglutide, the cardiometabolic drug was not found to be linked to worsened DR outcomes.

New AAO 2023 data suggests drugs like dapagliflozin and empagliflozin may provide greater protection against glaucoma than GLP-1 agonists or DDP-4 inhibitors.

New data from the Cleveland Clinic Cole Eye Institute showed patients not responding to anti-VEGF inhibitors could improve clinical and regimen parameters with short-term faricimab.

Oliver Gross, MD, discusses the unmet need in Alport Syndrome and the implications of study results presented at ASN Kidney Week 2023.

This new data suggests that hospital facilities in the US may need to plan for potentially atypical timing of bronchiolitis season once more for 2023.

The post hoc analysis of the phase 3 YOSEMITE/RHINE trials may support the therapeutic role of dual Ang-2/VEGF-A inhibition with faricimab for DME.

David Charles, MD, chief medical officer of the Alliance for Patient Access, delves into the far-reaching implications of alternative funding programs.

Results of the ZENITH-CKD trial provide evidence of the safety and efficacy profile of combination zibotentan plus dapagliflozin in patients with chronic kidney disease.

Primary results presented at ASN Kidney Week 2023 showed spironolactone missed the trial's primary endpoint.

The 2-year data from the PROTECT study confirms the sustained benefit of sparsentan in patients with IgA nephropathy.

Aldosterone synthase inhibition dose-dependently reduced albuminuria by up to 40% in participants with CKD, according to study results presented at ASN Kidney Week 2023.

Although the DUPLEX trial missed its primary endpoint of eGFR slope in patients with FSGS, results point to greater reductions in proteinuria and in risk of kidney failure with sparsentan use relative to irbesartan—making its case for becoming a standard of care for the glomerular disease.

A post hoc analysis of the phase 3 YOSEMITE and RHINE trials found significantly more patients had leakage resolution with faricmab than with aflibercept at Week 16.

In this segment of his interview, Dr. Chovatiya discussed some of the key safety data on secukinumab following the drug’s FDA approval for hidradenitis suppurativa.

Data presented at ASN Kidney Week 2023 described the effects of SGLT2 inhibition in young patients with Alport syndrome.

Results from the phase 3 YOSEMITE and RHINE trials show more than half of faricimab treat-and-extend patients met the criteria for a potential every-20-week dosing extension.

An analysis of Target-HTN provides new insight into the effects of lorundrostat among patients with uncontrolled or treatment-resistant hypertension.

Results presented at ASN Kidney Week 2023 highlighted the efficacy of twice weekly hemodialysis.

A subgroup analysis of hemodialysis patients treated with cognitive behavioral therapy for insomnia was presented at ASN Kidney Week 2023.

Rajiv Agarwal, MD, MS, provides insight into an analysis from ASN Kidney Week 2023 detailing the effect of early albuminuria reduction on risk of adverse kidney and cardiovascular outcomes in people with T2D and chronic kidney disease.

Presented at ASN Kidney Week 2023, results of the ENVISION trial provide the latest insight into effects of sibeprenlimab in management of IgA nephropathy as the nephrology community awaits the results of its ongoing phase 3 trial.

Our gastroenterology month in review highlights multiple FDA approvals, conference coverage from ACG 2023, and other top news in gastroenterology.

In our October 2023 endocrinology month in review, our editorial team highlights regulatory updates, pipeline news, and conference data capturing the attention of the field during the month.